Seattle Genetics seeks expanded Adcetris use in HL, sALCL
This article was originally published in Scrip
Executive Summary
Seattle Genetics is seeking the US FDA's approval to expand the labeling for Adcetris (brentuximab vedotin) for use in retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).